Oncology Letters最新文献

{"title":"Erratum: [Corrigendum] Inhibition of microRNA-221-5p induces osteogenic differentiation by directly targeting smad3 in myeloma bone disease mesenchymal stem cells.","authors":"Fang-Yi Fan, Rui Deng, Si-Han Lai, Qin Wen, Yunjing Zeng, Lei Gao, Yao Liu, Peiyan Kong, Jiangfan Zhong, Yi Su, Xi Zhang","doi":"10.3892/ol.2026.15533","DOIUrl":"10.3892/ol.2026.15533","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3892/ol.2019.10992.].</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"31 5","pages":"179"},"PeriodicalIF":2.2,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13034502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DNA hypermethylation of nonspecific cytotoxic cell receptor protein 1 and poor prognosis of pancreatic cancer.","authors":"Mai Nakamura, Teruki Hagiwara, Kazuhiko Yamada, Toru Igari, Yuki Fukumura, Akio Saiura, Nobuyuki Takemura, Norihiro Kokudo, Yuki I Kawamura","doi":"10.3892/ol.2026.15534","DOIUrl":"10.3892/ol.2026.15534","url":null,"abstract":"<p><p>Pancreatic cancer (PC) is a highly fatal malignancy and one of the leading causes of cancer-related deaths globally. Pancreatitis and inflammation-induced epigenetic changes, such as DNA methylation, have been reported to be involved in carcinogenesis and progression of PC. The present study examined the precise expression and DNA methylation status of nonspecific cytotoxic cell receptor protein 1 (NCCRP1), identified as a methylation target gene in esophageal cancers, in paired adjacent normal pancreas and PC tissues. NCCRP1 expression was immunohistochemically analyzed using formalin-fixed, paraffin-embedded sections of 73 patients with PC who underwent surgery. The DNA methylation status was analyzed in 52 paired adjacent normal and PC tissues using pyrosequencing. In normal pancreatic tissues, NCCRP1 expression was restricted to acinar cells and absent in ductal and islet cells. Most PCs (64/73) showed a loss of NCCRP1 expression, whereas NCCRP1 expression was observed in 9 cases. Among the NCCRP1-positive cases, 8 (89%) were classified as anaplastic carcinoma, an undifferentiated subtype of PC. When human PC cell lines were treated with 5-aza-2'-deoxycytidine, a DNA-methyltransferase inhibitor, NCCRP1 transcription was induced. Pyrosequencing analysis revealed that the promoter regions of NCCRP1 were highly DNA methylated in PC tissues compared with paired adjacent normal tissues. Furthermore, PC cases with DNA hypermethylated (>18.88%) NCCRP1 exhibited significantly poorer survival than those with relatively low levels of NCCRP1 methylation (P=0.0164). The data collectively suggested that NCCRP1 expression was frequently lost in PC, likely due to promoter hypermethylation, resulting in poor prognosis. This indicates the potential of NCCRP1 as a diagnostic and prognostic biomarker and a therapeutic target for patients with PC.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"31 5","pages":"178"},"PeriodicalIF":2.2,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13034516/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative complications in patients with chemotherapy-induced acute myeloid leukemia (Review).","authors":"Cen-Hung Lin, Hang-Tsung Liu, Ching-Hua Hsieh","doi":"10.3892/ol.2026.15530","DOIUrl":"10.3892/ol.2026.15530","url":null,"abstract":"<p><p>The present comprehensive review examines the latest clinical and translational research on postoperative complications in adult patients with chemotherapy-treated acute myeloid leukemia (AML) undergoing elective and emergency surgery. Patients with chemotherapy-treated AML face a markedly elevated risk of postoperative complications, with nearly one-half of patients experiencing complications such as severe infections and bleeding, with associated postoperative mortality rates of 10-20%. These risks are primarily driven by profound neutropenia and thrombocytopenia, impairing immune defense and hemostasis. A key clinical implication is that meticulous perioperative management can improve outcomes despite immunosuppression. Whenever possible, elective surgeries should be deferred until bone marrow recovery, with neutrophils at >1,000/µl and platelets at >50×10⁹/l. Management requires a multidisciplinary approach, involving hematologists optimizing blood counts with growth factors and transfusions, and infectious disease specialists guiding broad-spectrum antibiotic and antifungal prophylaxis. In urgent surgeries, aggressive supportive measures (colony-stimulating factors, transfusions and antimicrobials) are critical to prevent early infectious complications. Postoperatively, vigilant monitoring and early intervention are essential. This strategy includes intensive care support when indicated, surveillance for subtle signs of infection or bleeding, and the routine implementation of mechanical thromboprophylaxis. By adopting this strategy, teams can mitigate complications and improve outcomes for this high-risk population. Further research and coordinated clinical guidelines are required to refine perioperative strategies and improve outcomes.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"31 5","pages":"175"},"PeriodicalIF":2.2,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13034530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Retracted] MicroRNA-27a functions as an oncogene in human osteosarcoma by targeting CCNG1.","authors":"Tao Lin, Quanping Ma, Yuefeng Zhang, Hongfei Zhang, Jiapeng Yan, Changhong Gao","doi":"10.3892/ol.2026.15529","DOIUrl":"10.3892/ol.2026.15529","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.3892/ol.2017.7389.].</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"31 5","pages":"174"},"PeriodicalIF":2.2,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13034507/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of apalutamide dosage on the incidence of cutaneous adverse events and prostate-specific antigen reduction in patients with prostate cancer.","authors":"Takuya Matsuyama, Michio Kimura, Makiko Go, Shiori Yamada, Mitsuhiro Nishimura, Hiromi Murase, Rina Matsuyama, Eiseki Usami","doi":"10.3892/ol.2026.15527","DOIUrl":"10.3892/ol.2026.15527","url":null,"abstract":"<p><p>Apalutamide (Erleada^®; Janssen-Cilag Ltd.; Johnson & Johnson) is an effective therapeutic agent for prostate cancer; however, adverse events, particularly cutaneous toxicity, may lead to treatment discontinuation. Among Japanese patients, the incidence of cutaneous toxicity is relatively high and increased drug exposure has been reported in individuals with a small body size. In the present retrospective study, the effects of a reduced dose of apalutamide with stepwise escalation on the incidence of cutaneous toxicity and treatment efficacy were evaluated. Patients with prostate cancer who received apalutamide at Ogaki Municipal Hospital (Ogaki, Japan) between May 2019 and September 2024 were included in the present study. Based on their initial dose, patients were categorized into the standard-dose (240 mg; n=26) or reduced-dose (120 or 180 mg; n=20) group. The incidence and severity of cutaneous toxicity, time to the first cutaneous event and time to achieve prostate-specific antigen (PSA) <0.2 ng/ml and progression-free survival (PFS) were compared. Cutaneous toxicity occurred in 73.1 and 40.0% of the standard-dose and reduced-dose groups, respectively (P=0.036). Grade ≥3 toxicity was observed only in the standard-dose group (11.5%). The median time to the first cutaneous event was 63.0 vs. 45.5 days (P=0.193). The median time to achieve PSA <0.2 ng/ml was 120.0 days in both groups (P=0.822). The median PFS was not reached in the standard-dose group but was 693 days in the reduced-dose group (P=0.116). Overall, initiating apalutamide at a reduced dose with gradual escalation may mitigate the risk of cutaneous toxicity without compromising the PSA response. These findings provide clinically relevant insights, particularly for patients with a small body size, however further demonstration in larger prospective studies is warranted.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"31 5","pages":"172"},"PeriodicalIF":2.2,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13034515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone marrow metastasis from gastric cancer: A case report.","authors":"Xinyi Wei, Wenli Dai, Pengyi Deng","doi":"10.3892/ol.2026.15528","DOIUrl":"10.3892/ol.2026.15528","url":null,"abstract":"<p><p>Bone marrow metastasis from solid tumors is a rare clinical disease with an incidence of <1%. The present study reports on a case of gastric cancer with bone marrow metastasis. The patient presented with pancytopenia and lower back pain 2 years after radical gastrectomy and 1 year after completion of chemotherapy. Imaging examinations revealed no significant bone abnormalities in CT, diffuse reduction in T1 and T2 signals in spinal MRI, and a 'super-bone scan' appearance in whole-body bone scan. Subsequently, bone marrow aspiration confirmed bone marrow metastasis. A partial response was achieved following five cycles of chemotherapy. Nonetheless, the patient soon developed headaches and an MRI scan indicated meningeal metastasis. The patient died 6 months after the initial diagnosis of bone marrow metastasis. The present study aimed to review clinical characteristics and diagnostic methods of bone marrow metastasis.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"31 5","pages":"173"},"PeriodicalIF":2.2,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13034557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic treatment for a young patient with stage IV melanoma: A case report.","authors":"Xiaoyu Huang, Lianhai Zhao, Pingan Wang, Dong Xue","doi":"10.3892/ol.2025.15435","DOIUrl":"10.3892/ol.2025.15435","url":null,"abstract":"<p><p>Melanoma is a highly malignant tumor with a marked propensity for metastasis, and liver metastasis in particular is consistently associated with a poor prognosis. The current study reports the case of a 24-year-old man who presented with multiple systemic metastases 3 years after undergoing radical resection of a cutaneous melanoma. Genetic testing identified a BRAF mutation, which led to the initiation of targeted therapy using dabrafenib in combination with trametinib. After 2 months of treatment, imaging revealed a partial response in the liver metastases. However, by the fourth month, the disease progressed rapidly due to acquired resistance, causing the patient to succumb to liver failure and multiple organ dysfunction. The present case highlights the key need for vigilance, as even young patients with early-stage melanoma remain at risk of rapid disease progression. Therefore, implementing rigorous postoperative patient education and follow-up protocols is key to the early detection of recurrence and timely intervention. Simultaneously, the present case illustrates the challenge of acquired resistance to targeted therapy, underscoring the importance of developing strategies to overcome such resistance to potentially improve patient survival in the future.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"31 2","pages":"82"},"PeriodicalIF":2.2,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12863019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146113702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DHX15 overexpression suppresses colorectal cancer cell line proliferation.","authors":"Yuki Ii, Kosuke Saita, Toshiro Iwagawa, Shingo Ito, Kiichi Sugimoto, Kazuhiro Sakamoto, Sumiko Watanabe","doi":"10.3892/ol.2025.15433","DOIUrl":"10.3892/ol.2025.15433","url":null,"abstract":"<p><p>DEAH (Asp-Glu-Ala-His) box helicase 15 (DHX15) is a member of the DEAD box RNA helicase family that carries out a key role in innate immunity against viral infections. It is involved in tumorigenesis as a tumor-promoting factor in various types of cancer, but it has also been suggested to act as a tumor suppressor. However, the role of DHX15 in colorectal cancer (CRC) remains largely unknown. In the present study, we examined the role of DHX15 in CRC. Immunostaining of clinical samples from patients with CRC identified DHX15 proteins in the cell nuclei of both tumor and adjacent normal tissues. DHX15 overexpression was revealed to reduce the cell number of various CRC cell lines, as well as the number of Ki67-positive proliferating cells. However, the number of AC3-positive apoptotic cells was comparable between the control and DHX15-overexpressing cells. The possible downstream mechanisms of DHX15 were further examined which revealed that activation of the Wnt/β-catenin and NF-κB signaling pathways were not affected by DHX15 expression. However, DHX15 overexpression resulted in fewer LC3 puncta in HCT116 and DLD1 cells. Taken together, DHX15 may negatively affect CRC cell proliferation, and autophagy may potentially be involved in the downstream mechanism of DHX15.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"31 2","pages":"80"},"PeriodicalIF":2.2,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12863016/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146113736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High expression of G3BP1 is associated with poor prognosis in breast invasive carcinoma.","authors":"Jingjing Li, Zhiqiang Zong, Jian Shen, Jiahao Wang, Xuan Zhou, Wei Shi, Jia Li, Hong Zhao, Yunwen Yan, Fanfan Li","doi":"10.3892/ol.2025.15434","DOIUrl":"10.3892/ol.2025.15434","url":null,"abstract":"<p><p>Breast invasive carcinoma (BRCA) is the most common type of cancer affecting women worldwide. Biomarkers such as estrogen receptor, progesterone receptor and HER2 are currently utilized in clinical practice for breast cancer diagnosis; yet their sensitivity and specificity remain limited. However, Ras-GTPase-activating protein SH3 domain-binding protein 1 (G3BP1), an RNA-binding protein, has been implicated in tumor progression in various cancers, yet its clinical relevance and mechanistic role in BRCA still remain unclear. The present study integrated multi-omics data analysis and experimental validation to address this. G3BP1 mRNA and protein expression levels in BRCA were analyzed using The Cancer Genome Atlas, Tumor Immune Estimation Resource (TIMER) and Clinical Proteomic Tumor Analysis Consortium databases. Kaplan-Meier survival analysis and Cox regression were employed to evaluate the prognostic value of G3BP1. Gene set enrichment analysis (GSEA) was performed to identify associated signaling pathways and immune cell infiltration correlations were assessed using CIBERSORT and TIMER. Additionally, 38 samples of BRCA and adjacent normal tissue were collected for immunohistochemical (IHC) validation and diagnostic efficacy was evaluated using receiver operating characteristic (ROC) curves. G3BP1 was significantly upregulated in BRCA tissues at both mRNA and protein levels (P<0.05). High G3BP1 expression was associated with the advanced cancer lymph node stage (P=0.005) and a poor prognosis [overall survival, disease-free survival (DFS), distant metastasis-free survival and post-progression survival; all P<0.05]. Differential gene analysis identified 67 upregulated and 9 downregulated genes. GSEA revealed G3BP1 enrichment in key pathways such as PI3K/AKT/mTOR signaling and ubiquitin-mediated proteolysis. Immune analysis showed a significant positive association between G3BP1 and M2 macrophage infiltration (P<0.05) and a significant negative association between G3BP1 and CD8⁺ T cells (P<0.05). IHC confirmed higher G3BP1 expression in BRCA compared with normal tissues (P<0.001), with an area under the ROC curve (AUC) of 0.777 and a 5-year DFS prediction AUC of 0.730. The present findings indicate that G3BP1 is a potential independent prognostic biomarker for BRCA. Its upregulation promotes tumor progression by activating the PI3K/AKT/mTOR signaling pathway and modulating the tumor immune microenvironment. These findings provide a theoretical foundation for targeting G3BP1 in BRCA diagnosis and immunotherapy.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"31 2","pages":"81"},"PeriodicalIF":2.2,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12863017/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146113653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual role of IFNγ in reprogramming the undifferentiated pleomorphic sarcoma cell line JBT19 towards cytotoxic chemotherapy and antitumor immunity.","authors":"Pavla Taborska, Dmitry Stakheev, Daniel Smrz","doi":"10.3892/ol.2025.15431","DOIUrl":"10.3892/ol.2025.15431","url":null,"abstract":"<p><p>Soft tissue sarcomas are therapeutically challenging. Among soft tissue sarcoma subtypes, undifferentiated pleomorphic sarcoma (UPS) exhibits one of the most pronounced disparities between its comparatively higher responsiveness to immunotherapy and its limited responsiveness to conventional cytotoxic chemotherapy. The interplay between immunotherapy and cytotoxic chemotherapy is still largely unknown. Interferon-γ (IFNγ) is a key player in antitumor immunity and contributes to the modulation of the tumor microenvironment, which impacts both immune and cancer cells. The mechanism by which this interplay can affect cancer cell chemosensitivity and immune sensitivity is difficult to predict. The present study aimed to investigate the interplay of IFNγ signaling in the UPS cell line JBT19. It was identified that IFNγ treatment significantly decreased the proliferation of JBT19 cells and increased the surface expression levels of cluster of differentiation (CD)44, CD47, CD95 (Fas), major histocompatibility complex (MHC)-I and programmed death-ligand 1 (PD-L1). In addition, IFNγ strongly upregulated surface expression levels of MHC-II and converted JBT19 cells into docetaxel-resistant cells. The IFNγ-induced changes were sustained but reversible after 3 weeks of cell culture without IFNγ. Regardless of IFNγ treatment, JBT19 cells could elicit and amplify the adaptive immune response <i>in vitro</i>. The <i>in vitro</i> JBT19-reactive lymphocytes effectively eliminated both IFNγ-treated and non-treated JBT19 cells, thus overcoming IFNγ-induced chemoresistance. To the best of our knowledge, the present study demonstrated a dual role of IFNγ towards cancer cell chemoresistance and immunostimulatory potential for the first time. The present study findings may have potential implications for combining immunotherapy with cytotoxic chemotherapy in cancer treatment in the future.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"31 2","pages":"78"},"PeriodicalIF":2.2,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12746228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145864531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}